Search - tctmd.com

Displaying 1 - 20 of 73

Sort: Relevancy | Date

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

What’s Going to Be Big at TCT 2024?

News Opinion Editor's Corner TCT 2024

What’s Going to Be Big at TCT 2024?

Michael O'Riordan

October 17, 2024

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

October 27, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

News Conference News TCT 2022

Newest MitraClip Iteration Performs Well in the Real World: EXPAND G4

Yael L. Maxwell

September 23, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

News Opinion Editor's Corner TCT 2021

In-Person and Online: TCT to Showcase Imaging, Valves, DCBs, and More

November 01, 2021

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

News Conference News TCT 2020

Encouraging Results Seen for TAVR in Failed Surgical or TAVR Valves

October 17, 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

October 09, 2020

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

News Conference News TCT 2019

Early Mortality Rates After TAVR Halved in a Decade, With Some Gender Differences

October 09, 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

October 04, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.